Effect of XXXX on @entity2736 after hip replacement.

@entity1 @entity32 @entity174 @entity4040 @entity5018 @entity2918 @entity2736 @entity309
A double-blind, placebo-controlled study was made of the influence of the anti-inflammatory agent @entity5018 on @entity2736 after total hip replacement for @entity4040 , @entity174 or @entity309 . Seven drop-outs left 21 @entity1 on medication and 22 on placebo in two comparable groups. @entity2736 appeared in one third of the @entity1 in the @entity5018 group and in three fourths in the control group 12 months after surgery. Five @entity1 in the latter group developed true heterotopic bone, compared to one of the @entity1 on medication. @entity2736 was as common among osteoarthritic @entity1 as among others. There was no difference in the range of motion at 12 months postoperatively between @entity1 with and without @entity2736 . In the 22 @entity1 with @entity2736 this was demonstrated in all but eight within 6 weeks, and in only three did it appear later than 3 months postoperatively. Five of the six @entity1 who showed heterotopic bone with trabecular structure were male. Since @entity32 is a dominant feature in the postoperative phase, the effect of @entity5018 on @entity2736 is probably its inhibition of the synthesis of @entity2918 . This implies that prevention is most successful if commenced before or at the time of operation.
